UCB’s Zilbrysq (zilucoplan) Receives Approval from the EC to Treat Generalized Myasthenia Gravis (gMG)
Shots:
- The EC has granted approval to Zilbrysq as an add-on to standard therapy for treating anti-AChR antibody+ gMG, valid across all EU member states along with Iceland, Liechtenstein, and Norway. The drug availability will begin in Q1’24
- The approval was based results from the P-III (RAISE) trial evaluating the efficacy, safety and tolerability of Zilbrysq (0.3mg/kg, SC, 12wks.) vs PBO in adult patients, randomized 1:1, with anti-acetylcholine receptor (AChR) antibody-positive gMG
- The results revealed that at wk12, Zilbrysq showed rapid, consistent and significant improvements in various patient- and clinician-reported outcomes among mild-to-severe anti-AChR antibody+ gMG adult patients
Ref: UCB | Image: UCB
Related News:- UCB Receives the EC’s Approval for Rystiggo (rozanolixizumab) for the Treatment of Adults with Generalized Myasthenia Gravis (gMG)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
